Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 67

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 67
---
 in incomplete data;                        |

<div align='center'>34</div>

| ● | our inability to obtain approval from IRBs or ethics committees 
 to conduct clinical trials at their respective sites;           |

| ● | our inability to enroll and retain a sufficient number of patients 
 who meet the inclusion and exclusion criteria in a clinical trial; |

| ● | our inability to conduct a clinical trial in accordance with 
 regulatory requirements or our clinical protocols;           |

| ● | clinical sites and investigators deviating from trial protocol,                                                                              
 failing to conduct the trial in accordance with regulatory requirements, withdrawing from or dropping out of a trial, or becoming ineligible 
 to participate in a trial;                                                                                                                   |

| ● | failure of our clinical trial managers to satisfy their contractual 
 duties or meet expected deadlines;                                  |

| ● | manufacturing issues, including problems with manufacturing                                                   
 or timely obtaining from third parties sufficient quantities of a drug candidate for use in a clinical trial; |

| ● | ambiguous or negative interim results, or results that are inconsistent 
 with earlier results;                                                   |

| ● | feedback from the FDA, NMPA, EMA, Health Canada, an IRB, data                                                                         
 safety monitoring boards, or comparable entities, or results from earlier stage or concurrent studies in animals and clinical trials, 
 regarding Aptorum’s drug candidates, including which might require modification of a trial protocol;                                  |

| ● | unacceptable risk-benefit profile or unforeseen safety issues 
 or adverse side effects; and                                  |

| ● | a decision by the FDA, NMPA, EMA, Health Canada, an IRB, comparable                                                                    
 entities, or the Company, or recommendation by a data safety monitoring board or comparable regulatory entity, to suspend or terminate 
 clinical trials at any time for safety issues or for any other reason.                                                                 |

Changes in regulatory requirements
and guidance may also occur, and we may need to amend clinical trial protocols submitted to applicable regulatory authorities to reflect
these changes. Amendments may require us to resubmit clinical trial protocols to IRBs or ethics committees for re-examination, which may
increase the costs or time required to complete a clinical trial.

If we experience delays in
the completion of, or the termination of, a clinical trial, of any of Aptorum’s drug candidates, the commercial prospects of Aptorum’s
drug candidates will be harmed, and our ability to generate product sales revenues from any of those drug candidates will be delayed.
In addition, any delay in completing our clinical trials will increase our costs